Potential Role of Exosomes in Ischemic Stroke Treatment
Jiang L., Chen W., Ye J., Wang Y.
Clinical Trial on Stroke Research, published in Biomolecules (2022) — summary generated from the PubMed abstract.
Several human studies show positive signals, while research methods and sample sizes continue to develop.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Clinical Trial
- Journal
- Biomolecules (2022)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 35053263
- PMCID
- PMC8773818
- DOI
- 10.3390/biom12010115
- Citations
- 39
Abstract (original English)
Ischemic stroke is a life-threatening cerebral vascular disease and accounts for high disability and mortality worldwide. Currently, no efficient therapeutic strategies are available for promoting neurological recovery in clinical practice, except rehabilitation. The majority of neuroprotective drugs showed positive impact in pre-clinical studies but failed in clinical trials. Therefore, there is an urgent demand for new promising therapeutic approaches for ischemic stroke treatment. Emerging evidence suggests that exosomes mediate communication between cells in both physiological and pathological conditions. Exosomes have received extensive attention for therapy following a stroke, because of their unique characteristics, such as the ability to cross the blood brain-barrier, low immunogenicity, and low toxicity. An increasing number of studies have demonstrated positively neurorestorative effects of exosome-based therapy, which are largely mediated by the microRNA cargo. Herein, we review the current knowledge of exosomes, the relationships between exosomes and stroke, and the therapeutic effects of exosome-based treatments in neurovascular remodeling processes after stroke. Exosomes provide a viable and prospective treatment strategy for ischemic stroke patients.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Several human studies show positive signals, while research methods and sample sizes continue to develop.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level AMeta-analysisEurope PMC
Stem cell therapy for ischemic stroke: neuroimaging approaches and evidence from a systematic review
Meta-analysis on Stroke Research, published in Front Neurol (2026) — summary generated from the PubMed abstract.
- 2026
Front Neurol - Level AMeta-analysisEurope PMC
Efficacy and safety of stem cell therapy for myocardial infarction and heart failure: an updated systematic review and meta-analysis of randomized controlled trials
Meta-analysis with a reported sample of 3345 on Cardiovascular Disease, Stroke Research, published in Syst Rev (2026) — summary generated from the PubMed abstract.
- 2026
- n = 3345
Syst Rev - Level AMeta-analysisEurope PMC
Safety and Efficacy of Transendocardial Stem Cells Therapy in Chronic Ischemic Heart Failure: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Meta-analysis on Cardiovascular Disease, Stroke Research, published in Curr Cardiol Rev (2025) — summary generated from the PubMed abstract.
- 2025
Curr Cardiol Rev - Level AMeta-analysisEurope PMC
Efficacy and Potential Mechanisms of Umbilical Cord-Derived Mesenchymal Stem Cells in the Treatment of Ischemic Stroke in Animal Models: A Meta-Analysis
Meta-analysis on Stroke Research, published in CNS Neurosci Ther (2025) — summary generated from the PubMed abstract.
- 2025
CNS Neurosci Ther5 citations - Level AMeta-analysisPubMed
The inconclusive superiority debate of allogeneic versus autologous MSCs in treating patients with HFrEF: a systematic review and meta-analysis of RCTs.
Meta-analysis with a reported sample of 1184 on Cardiovascular Disease, Stroke Research, published in Stem Cell Res Ther (2025) — summary generated from the PubMed abstract.
- 2025
- n = 1184
Stem Cell Res Ther2 citations - Level ASystematic ReviewEurope PMC
In vitro and In vivo Studies on Mesenchymal Stem Cells for Ischemic Stroke Therapy: A Scoping Review of The Therapeutic Effect
Systematic Review on Stroke Research, published in Stem Cells Cloning (2025) — summary generated from the PubMed abstract.
- 2025
Stem Cells Cloning